Amphipathic molecules as cholesterol and other lipid uptake inhibitors
CA 2249459 A1 · Owner: Boffelli, Dario · Inventors: Hauser, Helmut; Boffelli, Dario
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Cholesterol biosynthesis can be inhibited by suitable inhibitors such as the , statins. However, hypercholesterolaemia whether familial or diet-induced, and more generally hyperlipidaemia are not adequately addressed by cholesterol biosynthesis inhibitors alone, since the body's cholesterol is acquired by uptake from the diet as well as by endogenous synthesis. Lipid is also taken up from the gut. This problem is addressed by providing one or more molecules having amphipathic regions to inhibit the uptake of cholesterol and other , lipids, from the gut. Obesity may also be treated or prevented in this way as , may atherosclerosis. Examples of suitable molecules having amphipathic …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 27, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 27, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 27, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.